Relypsa Inc (RLYP) 35.39 $RLYP
Relypsa Announces New Employment Inducement Grants
GlobeNewswire - Tue Apr 21, 7:30AM CDT
Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on April 15, 2015, the compensation committee of the company's board of directors granted eight new employees options to purchase an aggregate of 33,300 shares of the company's common stock with a per share exercise price of $36.79, the closing trading price on the grant date. The stock options were granted pursuant to the Relypsa, Inc. 2014 Employment Commencement Incentive Plan, which was approved by the company's board of directors in June 2014 under Rule 5653(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the company.
RLYP: 35.39 (-0.54)
Relypsa Presents New Data on the Importance of Renin-Angiotensin-Aldosterone-System Inhibitor (RAASi) Therapy in Patients With Cardio-Renal Comorbidities at the Academy of Managed Care Pharmacy's 27th Annual Meeting
GlobeNewswire - Wed Apr 08, 7:30AM CDT
Relypsa Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that results from retrospective analyses of a large medical database assessing the use of renin-angiotensin-aldosterone-system inhibitor (RAASi) therapy in patients with chronic kidney disease (CKD) and/or heart failure (HF) will be presented in two posters at the Academy of Managed Care Pharmacy's (AMCP) 27 Annual Meeting and Expo. The two posters examine, respectively, the extent to which patients with CKD and/or HF are receiving guideline-recommended doses of RAASi therapy and potential associations between sub-maximum dosing, cardio-renal events and mortality. In addition, Relypsa is sponsoring a Science & Innovation Theater session at the Meeting to review the latest data in managing cardio-renal patients with hyperkalemia.
RLYP: 35.39 (-0.54)
Why Relypsa, Inc. (RLYP) Could Be Positioned for a Slump - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Apr 06, 7:34AM CDT
Relypsa, Inc. (RLYP) has witnessed a significant price decline in the past four weeks, and it has lately seen substantial negative earnings estimate revisions as well.
MNK: 122.95 (-2.22), RLYP: 35.39 (-0.54)
Relypsa Presents Sub-Group Analysis From Phase 3 Study of Patiromer FOS in Patients With Advanced Chronic Kidney Disease at 2015 National Kidney Foundation Spring Clinical Meeting
GlobeNewswire - Thu Mar 26, 6:00PM CDT
Relypsa Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that data from a Phase 3 clinical program showing that Patiromer for Oral Suspension (Patiromer FOS), the Company's lead product candidate, was effective in reducing potassium levels and preventing a recurrence of hyperkalemia in patients with advanced (stage 4-5) chronic kidney disease (CKD) receiving ongoing treatment with renin-angiotensin-aldosterone system (RAAS) inhibitors were presented today as a poster at the National Kidney Foundation 2015 Spring Clinical Meeting. The results are from a sub-group analysis of the two part Phase 3 trial, OPAL-HK, conducted under a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) that was led by Matthew Weir, M.D., Professor and Director, Division of Nephrology, University of Maryland School of Medicine.
RLYP: 35.39 (-0.54)
Relypsa Highlights Multiple Presentations of Patiromer for Oral Suspension at the 2015 World Congress of Nephrology
GlobeNewswire - Mon Mar 16, 7:30AM CDT
Relypsa Inc. (Nasdaq:RLYP), a biopharmaceutical company, today highlighted multiple data presentations of Patiromer for Oral Suspension (FOS) at the 2015 World Congress of Nephrology. Patiromer FOS, Relypsa's lead product candidate, is an oral potassium binder being developed for the treatment of hyperkalemia.
RLYP: 35.39 (-0.54)
Relypsa's Patiromer FOS successful controlling elevated potassium in heart failure patients
Seeking Alpha - at Seeking Alpha - Sat Mar 14, 6:36PM CDT
RLYP: 35.39 (-0.54)
Relypsa Announces Phase 2 Data Showing Efficacy of Patiromer FOS in Heart Failure Patients With Chronic Kidney Disease at ACC Scientific Session
GlobeNewswire - Sat Mar 14, 7:30AM CDT
Sub-group Analysis of AMETHYST-DN Trial Results Led by Bertram Pitt, M.D.
RLYP: 35.39 (-0.54)
Relypsa reports 4Q loss
Automated Insights - Wed Mar 11, 5:04PM CDT
REDWOOD CITY, Calif. (AP) _ Relypsa Inc. (RLYP) on Wednesday reported a loss of $27.6 million in its fourth quarter.
RLYP: 35.39 (-0.54)
Relypsa misses by $0.12
Seeking Alpha - at Seeking Alpha - Wed Mar 11, 3:26PM CDT
RLYP: 35.39 (-0.54)
Relypsa Announces Fourth Quarter and Full Year 2014 Financial Results
GlobeNewswire - Wed Mar 11, 3:10PM CDT
Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today reported financial results for the fourth quarter and year ended December 31, 2014.
RLYP: 35.39 (-0.54)
Relypsa to Present at 27th Annual ROTH Conference
GlobeNewswire - Mon Mar 02, 7:30AM CST
Relypsa, Inc. (Nasdaq:RLYP), today announced that Kristine M. Ball, senior vice president and chief financial officer, will present at the 27 Annual ROTH Conference on March 10, 2015 at 9:30 a.m. PT.
RLYP: 35.39 (-0.54)
Nasdaq stocks posting largest percentage increases
AP - Tue Feb 24, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
FSLR: 63.88 (+0.77), TSRO: 62.25 (-1.08), STAA: 9.01 (unch), AFMD: 7.94 (+0.11), CERU: 5.99 (-0.20), RLYP: 35.39 (-0.54), TSEM: 17.36 (-0.07), PTCT: 70.98 (unch), DEPO: 27.14 (+0.65), DGLY: 13.13 (+0.08), GTLS: 40.68 (+0.51)
Notable earnings after Tuesday’s close
Seeking Alpha - at Seeking Alpha - Mon Feb 23, 4:35PM CST
AMRS: 2.61 (unch), AWAY: 32.27 (+0.76), HWAY: 18.99 (-0.08), FLTX: 47.90 (+0.56), HLS: 46.35 (+0.48), RRC: 60.72 (+0.93), DY: 48.32 (+0.41), MATX: 42.01 (+0.77), NYMT: 7.87 (+0.05), NSTG: 12.25 (-0.02), PZZA: 61.35 (-0.57), SGY: 16.54 (-0.83), HEP: 33.25 (+0.13), ARC: 9.05 (-0.01), BGFV: 12.36 (+0.16), RJET: 13.09 (-0.07), RLYP: 35.39 (-0.54), SAM: 261.44 (-2.60), DWA: 26.12 (-0.26), NKTR: 10.90 (+0.16), FSLR: 63.88 (+0.77), NFX: 37.77 (+0.79), KONA: 26.24 (-0.63), BBRG: 14.98 (-0.02), HEI: 59.00 (-0.34), CLR: 51.80 (+0.98), ACAS: 15.18 (+0.04), RUBI: 17.36 (-0.23), HURN: 66.98 (-0.18), GB: 54.53 (-0.02), BNFT: 36.87 (-0.20), AWK: 54.26 (+0.38), NUVA: 43.38 (+0.10), BOOM: 13.03 (-0.02), CENX: 13.28 (+0.17), GNMK: 10.51 (-0.22), QEP: 22.17 (-0.01), FMI: 48.71 (-0.96), KRA: 20.05 (+0.37), DPM: 39.93 (+0.29), JAZZ: 186.13 (-0.41), INFI: 14.71 (-0.28), EPR: 59.11 (-0.21), EXEL: 3.12 (+0.05), CBI: 49.62 (-1.62), NDSN: 80.39 (+0.80), ORA: 37.84 (+0.22), CPRT: 37.19 (-0.16), SM: 55.21 (+1.23), HPQ: 33.51 (+0.30), NLY: 10.27 (+0.02), LC: 19.01 (-0.34), DYN: 33.28 (+0.24), CLGX: 35.61 (-0.03), SLCA: 36.94 (+0.70), EIX: 60.01 (-0.49), MMSI: 18.79 (+0.45)
Relypsa to Present at 17th Annual BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 02, 9:05AM CST
Relypsa, Inc. (Nasdaq:RLYP), today announced that John A. Orwin, president and chief executive officer, will present at the 17 Annual BIO CEO & Investor Conference on February 10, 2015 at 9:00 a.m. ET.
RLYP: 35.39 (-0.54)
ZS Pharma:: A Few Months Behind, But An Inpatient Advantage
Investing Doc - at Seeking Alpha - Thu Jan 29, 7:02AM CST
ZSPH: 42.50 (+1.08), RLYP: 35.39 (-0.54)
Relypsa Announces Helen Torley, M.B. Ch.B., M.R.C.P. Joins Board of Directors
GlobeNewswire - Thu Jan 22, 3:30PM CST
Relypsa, Inc. (Nasdaq:RLYP), today announced that Helen Torley, M.B. Ch.B., M.R.C.P., has been appointed to the company's board of directors, bringing the number of directors to nine. Dr. Torley, current president and chief executive officer of Halozyme Therapeutics, brings to the board significant industry experience and deep knowledge and expertise in development and commercialization of biopharmaceutical products, including several recent successful product launches.
RLYP: 35.39 (-0.54)
Relypsa: Unglamorous Niche, Exciting Opportunity
Investing Doc - at Seeking Alpha - Tue Jan 20, 12:28PM CST
RLYP: 35.39 (-0.54)
Relypsa Announces New Employment Inducement Grants
GlobeNewswire - Tue Apr 21, 7:30AM CDT
Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on April 15, 2015, the compensation committee of the company's board of directors granted eight new employees options to purchase an aggregate of 33,300 shares of the company's common stock with a per share exercise price of $36.79, the closing trading price on the grant date. The stock options were granted pursuant to the Relypsa, Inc. 2014 Employment Commencement Incentive Plan, which was approved by the company's board of directors in June 2014 under Rule 5653(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the company.
RLYP: 35.39 (-0.54)
Relypsa Presents New Data on the Importance of Renin-Angiotensin-Aldosterone-System Inhibitor (RAASi) Therapy in Patients With Cardio-Renal Comorbidities at the Academy of Managed Care Pharmacy's 27th Annual Meeting
GlobeNewswire - Wed Apr 08, 7:30AM CDT
Relypsa Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that results from retrospective analyses of a large medical database assessing the use of renin-angiotensin-aldosterone-system inhibitor (RAASi) therapy in patients with chronic kidney disease (CKD) and/or heart failure (HF) will be presented in two posters at the Academy of Managed Care Pharmacy's (AMCP) 27 Annual Meeting and Expo. The two posters examine, respectively, the extent to which patients with CKD and/or HF are receiving guideline-recommended doses of RAASi therapy and potential associations between sub-maximum dosing, cardio-renal events and mortality. In addition, Relypsa is sponsoring a Science & Innovation Theater session at the Meeting to review the latest data in managing cardio-renal patients with hyperkalemia.
RLYP: 35.39 (-0.54)
Why Relypsa, Inc. (RLYP) Could Be Positioned for a Slump - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Apr 06, 7:34AM CDT
Relypsa, Inc. (RLYP) has witnessed a significant price decline in the past four weeks, and it has lately seen substantial negative earnings estimate revisions as well.
MNK: 122.95 (-2.22), RLYP: 35.39 (-0.54)
Relypsa Presents Sub-Group Analysis From Phase 3 Study of Patiromer FOS in Patients With Advanced Chronic Kidney Disease at 2015 National Kidney Foundation Spring Clinical Meeting
GlobeNewswire - Thu Mar 26, 6:00PM CDT
Relypsa Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that data from a Phase 3 clinical program showing that Patiromer for Oral Suspension (Patiromer FOS), the Company's lead product candidate, was effective in reducing potassium levels and preventing a recurrence of hyperkalemia in patients with advanced (stage 4-5) chronic kidney disease (CKD) receiving ongoing treatment with renin-angiotensin-aldosterone system (RAAS) inhibitors were presented today as a poster at the National Kidney Foundation 2015 Spring Clinical Meeting. The results are from a sub-group analysis of the two part Phase 3 trial, OPAL-HK, conducted under a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) that was led by Matthew Weir, M.D., Professor and Director, Division of Nephrology, University of Maryland School of Medicine.
RLYP: 35.39 (-0.54)
Relypsa Highlights Multiple Presentations of Patiromer for Oral Suspension at the 2015 World Congress of Nephrology
GlobeNewswire - Mon Mar 16, 7:30AM CDT
Relypsa Inc. (Nasdaq:RLYP), a biopharmaceutical company, today highlighted multiple data presentations of Patiromer for Oral Suspension (FOS) at the 2015 World Congress of Nephrology. Patiromer FOS, Relypsa's lead product candidate, is an oral potassium binder being developed for the treatment of hyperkalemia.
RLYP: 35.39 (-0.54)
Relypsa's Patiromer FOS successful controlling elevated potassium in heart failure patients
Seeking Alpha - at Seeking Alpha - Sat Mar 14, 6:36PM CDT
RLYP: 35.39 (-0.54)
Relypsa Announces Phase 2 Data Showing Efficacy of Patiromer FOS in Heart Failure Patients With Chronic Kidney Disease at ACC Scientific Session
GlobeNewswire - Sat Mar 14, 7:30AM CDT
Sub-group Analysis of AMETHYST-DN Trial Results Led by Bertram Pitt, M.D.
RLYP: 35.39 (-0.54)
Relypsa reports 4Q loss
Automated Insights - Wed Mar 11, 5:04PM CDT
REDWOOD CITY, Calif. (AP) _ Relypsa Inc. (RLYP) on Wednesday reported a loss of $27.6 million in its fourth quarter.
RLYP: 35.39 (-0.54)
Relypsa misses by $0.12
Seeking Alpha - at Seeking Alpha - Wed Mar 11, 3:26PM CDT
RLYP: 35.39 (-0.54)
Relypsa Announces Fourth Quarter and Full Year 2014 Financial Results
GlobeNewswire - Wed Mar 11, 3:10PM CDT
Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today reported financial results for the fourth quarter and year ended December 31, 2014.
RLYP: 35.39 (-0.54)
Relypsa to Present at 27th Annual ROTH Conference
GlobeNewswire - Mon Mar 02, 7:30AM CST
Relypsa, Inc. (Nasdaq:RLYP), today announced that Kristine M. Ball, senior vice president and chief financial officer, will present at the 27 Annual ROTH Conference on March 10, 2015 at 9:30 a.m. PT.
RLYP: 35.39 (-0.54)
Nasdaq stocks posting largest percentage increases
AP - Tue Feb 24, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
FSLR: 63.88 (+0.77), TSRO: 62.25 (-1.08), STAA: 9.01 (unch), AFMD: 7.94 (+0.11), CERU: 5.99 (-0.20), RLYP: 35.39 (-0.54), TSEM: 17.36 (-0.07), PTCT: 70.98 (unch), DEPO: 27.14 (+0.65), DGLY: 13.13 (+0.08), GTLS: 40.68 (+0.51)
Notable earnings after Tuesday’s close
Seeking Alpha - at Seeking Alpha - Mon Feb 23, 4:35PM CST
AMRS: 2.61 (unch), AWAY: 32.27 (+0.76), HWAY: 18.99 (-0.08), FLTX: 47.90 (+0.56), HLS: 46.35 (+0.48), RRC: 60.72 (+0.93), DY: 48.32 (+0.41), MATX: 42.01 (+0.77), NYMT: 7.87 (+0.05), NSTG: 12.25 (-0.02), PZZA: 61.35 (-0.57), SGY: 16.54 (-0.83), HEP: 33.25 (+0.13), ARC: 9.05 (-0.01), BGFV: 12.36 (+0.16), RJET: 13.09 (-0.07), RLYP: 35.39 (-0.54), SAM: 261.44 (-2.60), DWA: 26.12 (-0.26), NKTR: 10.90 (+0.16), FSLR: 63.88 (+0.77), NFX: 37.77 (+0.79), KONA: 26.24 (-0.63), BBRG: 14.98 (-0.02), HEI: 59.00 (-0.34), CLR: 51.80 (+0.98), ACAS: 15.18 (+0.04), RUBI: 17.36 (-0.23), HURN: 66.98 (-0.18), GB: 54.53 (-0.02), BNFT: 36.87 (-0.20), AWK: 54.26 (+0.38), NUVA: 43.38 (+0.10), BOOM: 13.03 (-0.02), CENX: 13.28 (+0.17), GNMK: 10.51 (-0.22), QEP: 22.17 (-0.01), FMI: 48.71 (-0.96), KRA: 20.05 (+0.37), DPM: 39.93 (+0.29), JAZZ: 186.13 (-0.41), INFI: 14.71 (-0.28), EPR: 59.11 (-0.21), EXEL: 3.12 (+0.05), CBI: 49.62 (-1.62), NDSN: 80.39 (+0.80), ORA: 37.84 (+0.22), CPRT: 37.19 (-0.16), SM: 55.21 (+1.23), HPQ: 33.51 (+0.30), NLY: 10.27 (+0.02), LC: 19.01 (-0.34), DYN: 33.28 (+0.24), CLGX: 35.61 (-0.03), SLCA: 36.94 (+0.70), EIX: 60.01 (-0.49), MMSI: 18.79 (+0.45)
Relypsa to Present at 17th Annual BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 02, 9:05AM CST
Relypsa, Inc. (Nasdaq:RLYP), today announced that John A. Orwin, president and chief executive officer, will present at the 17 Annual BIO CEO & Investor Conference on February 10, 2015 at 9:00 a.m. ET.
RLYP: 35.39 (-0.54)
ZS Pharma:: A Few Months Behind, But An Inpatient Advantage
Investing Doc - at Seeking Alpha - Thu Jan 29, 7:02AM CST
ZSPH: 42.50 (+1.08), RLYP: 35.39 (-0.54)
Relypsa Announces Helen Torley, M.B. Ch.B., M.R.C.P. Joins Board of Directors
GlobeNewswire - Thu Jan 22, 3:30PM CST
Relypsa, Inc. (Nasdaq:RLYP), today announced that Helen Torley, M.B. Ch.B., M.R.C.P., has been appointed to the company's board of directors, bringing the number of directors to nine. Dr. Torley, current president and chief executive officer of Halozyme Therapeutics, brings to the board significant industry experience and deep knowledge and expertise in development and commercialization of biopharmaceutical products, including several recent successful product launches.
RLYP: 35.39 (-0.54)
Relypsa: Unglamorous Niche, Exciting Opportunity
Investing Doc - at Seeking Alpha - Tue Jan 20, 12:28PM CST
RLYP: 35.39 (-0.54)
